QQQ   275.95 (-0.45%)
AAPL   114.09 (-0.76%)
MSFT   207.26 (-1.04%)
FB   261.79 (+1.94%)
GOOGL   1,466.02 (+0.50%)
AMZN   3,144.88 (-0.92%)
TSLA   419.07 (-0.51%)
NVDA   529.03 (+1.46%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.71 (+1.99%)
AMD   81.77 (+2.88%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.10 (-1.19%)
NFLX   493.48 (+0.58%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
QQQ   275.95 (-0.45%)
AAPL   114.09 (-0.76%)
MSFT   207.26 (-1.04%)
FB   261.79 (+1.94%)
GOOGL   1,466.02 (+0.50%)
AMZN   3,144.88 (-0.92%)
TSLA   419.07 (-0.51%)
NVDA   529.03 (+1.46%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.71 (+1.99%)
AMD   81.77 (+2.88%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.10 (-1.19%)
NFLX   493.48 (+0.58%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
QQQ   275.95 (-0.45%)
AAPL   114.09 (-0.76%)
MSFT   207.26 (-1.04%)
FB   261.79 (+1.94%)
GOOGL   1,466.02 (+0.50%)
AMZN   3,144.88 (-0.92%)
TSLA   419.07 (-0.51%)
NVDA   529.03 (+1.46%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.71 (+1.99%)
AMD   81.77 (+2.88%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.10 (-1.19%)
NFLX   493.48 (+0.58%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
QQQ   275.95 (-0.45%)
AAPL   114.09 (-0.76%)
MSFT   207.26 (-1.04%)
FB   261.79 (+1.94%)
GOOGL   1,466.02 (+0.50%)
AMZN   3,144.88 (-0.92%)
TSLA   419.07 (-0.51%)
NVDA   529.03 (+1.46%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.71 (+1.99%)
AMD   81.77 (+2.88%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.10 (-1.19%)
NFLX   493.48 (+0.58%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
Log in
NYSE:JNJ

Johnson & Johnson Stock Forecast, Price & News

$147.06
-0.05 (-0.03 %)
(As of 09/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$146.06
Now: $147.06
$147.92
50-Day Range
$144.21
MA: $149.17
$153.83
52-Week Range
$109.16
Now: $147.06
$157.00
Volume6.77 million shs
Average Volume8.39 million shs
Market Capitalization$387.18 billion
P/E Ratio21.50
Dividend Yield2.75%
Beta0.68
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; sterilization and disinfection products to reduce surgical infection; diabetes care products; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. It has research and collaboration alliance with Morphic Therapeutic. The company was incorporated in 1887 and is based in New Brunswick, New Jersey.
Read More
Johnson & Johnson logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 4.2Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.46 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP47816010
Phone732-524-0400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$82.06 billion
Cash Flow$11.42 per share
Book Value$22.60 per share

Profitability

Net Income$15.12 billion

Miscellaneous

Employees132,200
Outstanding Shares2,632,823,000
Market Cap$387.18 billion
Next Earnings Date10/13/2020 (Confirmed)
OptionableOptionable
$147.06
-0.05 (-0.03 %)
(As of 09/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive JNJ News and Ratings via Email

Sign-up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions

How has Johnson & Johnson's stock been impacted by COVID-19?

Johnson & Johnson's stock was trading at $131.80 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, JNJ stock has increased by 11.6% and is now trading at $147.06.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Johnson & Johnson?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Johnson & Johnson
.

When is Johnson & Johnson's next earnings date?

Johnson & Johnson is scheduled to release its next quarterly earnings announcement on Tuesday, October 13th 2020.
View our earnings forecast for Johnson & Johnson
.

How can I listen to Johnson & Johnson's earnings call?

Johnson & Johnson will be holding an earnings conference call on Tuesday, October 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings results on Thursday, July, 16th. The company reported $1.67 earnings per share for the quarter, beating analysts' consensus estimates of $1.50 by $0.17. The firm earned $18.34 billion during the quarter, compared to analyst estimates of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The firm's revenue was down 10.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.58 EPS.
View Johnson & Johnson's earnings history
.

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson announced a quarterly dividend on Monday, July 20th. Stockholders of record on Tuesday, August 25th will be given a dividend of $1.01 per share on Tuesday, September 8th. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date of this dividend is Monday, August 24th.
View Johnson & Johnson's dividend history
.

How will Johnson & Johnson's stock buyback program work?

Johnson & Johnson announced that its Board of Directors has initiated a share buyback plan on Monday, December 17th 2018, which allows the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 1.5% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's leadership believes its shares are undervalued.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson issued an update on its FY20 earnings guidance on Wednesday, August, 19th. The company provided EPS guidance of $7.75-7.95 for the period, compared to the Thomson Reuters consensus estimate of $7.87. The company issued revenue guidance of $81-82.5 billion, compared to the consensus revenue estimate of $80.54 billion.

What price target have analysts set for JNJ?

15 analysts have issued 12 month price objectives for Johnson & Johnson's shares. Their forecasts range from $155.00 to $182.00. On average, they anticipate Johnson & Johnson's share price to reach $163.93 in the next twelve months. This suggests a possible upside of 11.5% from the stock's current price.
View analysts' price targets for Johnson & Johnson
.

Has Johnson & Johnson been receiving favorable news coverage?

Press coverage about JNJ stock has been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Johnson & Johnson earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future.
View the latest news about Johnson & Johnson
.

Are investors shorting Johnson & Johnson?

Johnson & Johnson saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 10,560,000 shares, an increase of 12.0% from the August 15th total of 9,430,000 shares. Based on an average daily trading volume, of 6,470,000 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.4% of the shares of the company are short sold.
View Johnson & Johnson's Short Interest
.

Who are some of Johnson & Johnson's key competitors?

What other stocks do shareholders of Johnson & Johnson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Johnson & Johnson investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Walt Disney (DIS), NVIDIA (NVDA), Intel (INTC), JPMorgan Chase & Co. (JPM), Cisco Systems (CSCO), Procter & Gamble (PG) and AbbVie (ABBV).

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the following people:
  • Mr. Alex Gorsky, Chairman & CEO (Age 59)
  • Mr. Joseph J. Wolk CPA, Exec. VP & CFO (Age 52)
  • Dr. Paulus A. Stoffels, Chief Scientific Officer (Age 57)
  • Mr. Michael H. Ullmann, Exec. VP & Gen. Counsel (Age 60)
  • Mr. Joaquin Duato, Vice Chairman of Exec. Committee (Age 56)

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

How do I buy shares of Johnson & Johnson?

Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Johnson & Johnson's stock price today?

One share of JNJ stock can currently be purchased for approximately $147.06.

How big of a company is Johnson & Johnson?

Johnson & Johnson has a market capitalization of $387.18 billion and generates $82.06 billion in revenue each year. The company earns $15.12 billion in net income (profit) each year or $8.68 on an earnings per share basis. Johnson & Johnson employs 132,200 workers across the globe.

What is Johnson & Johnson's official website?

The official website for Johnson & Johnson is www.jnj.com.

How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.